Compare AngloGold Ashanti Limited (AU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Neurocrine Biosciences Inc — how do they compare? AngloGold Ashanti Limited trades at $78.5 (market cap $40.62B), while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.30B). The key difference: AngloGold Ashanti Limited is far larger — about 2.3× Neurocrine Biosciences Inc's market cap, and AngloGold Ashanti Limited pays a 5.73% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AU | NBIX | |
|---|---|---|
Market Cap | $40.62B | $17.30B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $180.55 |
52-Week Low | $46.25 | $123.10 |
Enterprise Value | $39.75B | $16.39B |
Dividend Yield | 5.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $79.76, down 2.85% amid bearish technical signals. The stock shows strong fundamentals with 2025 revenue growth to $9.89B and net income of $2.64B, supported by a 31.11% net margin. Recent Q1 2026 earnings beat expectations at $2.52 EPS versus $2.27 forecast. Analyst consensus remains positive with a $118.60 price target, though technical indicators show selling pressure with support at $77-79 levels.
The outlook remains favorable given robust cash flow growth and geographic diversification, but faces risks from gold price volatility and recent technical weakness. With 64% analyst buy ratings and significant upside to price targets, the stock presents value opportunity for patient investors despite near-term bearish momentum.
Neurocrine Biosciences (NBIX) trades at $174.10, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and support at $173. The company demonstrates robust fundamentals with Q1 2026 revenue growth of 44% year-over-year to $811 million and consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected. Recent pipeline advancements include Phase 2 studies for crinecerfont and positive VYKAT XR data presented at ENDO 2026.
NBIX presents compelling growth prospects with analyst consensus price target of $195.75 (12% upside) and 86% buy ratings. Key opportunities include blockbuster drug performance and strategic acquisitions, while risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's current valuation at 26.5x P/E reflects growth expectations but requires continued execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
